Search Results

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Inc. today announced that it will participate in the Virtual Life Sciences Investor Forum taking place June 20, 2024.

June 17, 2024

·

1 min read

BioMidwest

Longeveron® to Attend BIO International Convention 2024

Longeveron Inc. announced that the Company will participate in the BIO International Convention taking place June 3-6, 2024 at the San Diego Convention Center.

May 28, 2024

·

6 min read

BioMidwest

Longeveron to Present at the Planet MicroCap Showcase

Longeveron Inc. announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.

April 25, 2024

·

1 min read

BioMidwest

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron Inc. announced the launch of its contract development and manufacturing business at the Company’s 15,000 square feet state-of-the-art Good Manufacturing Practice facility.

June 3, 2024

·

8 min read

Deals

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share.

June 17, 2024

·

8 min read

Business

Longeveron Announces Board of Directors Planned Transitions

Longeveron Inc., a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced planned transitions on its Board of Directors.

May 10, 2024

·

9 min read

BioMidwest

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron Inc. announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024.

June 18, 2024

·

7 min read

BioMidwest

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

Longeveron Inc. announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.

April 8, 2024

·

13 min read

Deals

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares.

April 17, 2024

·

8 min read

Business

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2024 and provided a business update.

May 14, 2024

·

15 min read